283 related articles for article (PubMed ID: 16430342)
1. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain.
Raskin J; Smith TR; Wong K; Pritchett YL; D'Souza DN; Iyengar S; Wernicke JF
J Palliat Med; 2006 Feb; 9(1):29-40. PubMed ID: 16430342
[TBL] [Abstract][Full Text] [Related]
2. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
Wernicke JF; Wang F; Pritchett YL; Smith TR; Raskin J; D'Souza DN; Iyengar S; Chappell AS
Pain Med; 2007 Sep; 8(6):503-13. PubMed ID: 17716324
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients.
Wasan AD; Ossanna MJ; Raskin J; Wernicke JF; Robinson MJ; Hall JA; Edwards SE; Lipsius S; Meyers AL; McCarberg BH
Curr Drug Saf; 2009 Jan; 4(1):22-9. PubMed ID: 19149522
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial.
Wernicke JF; Raskin J; Rosen A; Pritchett YL; D'Souza DN; Iyengar S; Knopp K; Le TK
Curr Ther Res Clin Exp; 2006 Sep; 67(5):283-304. PubMed ID: 24678103
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.
Quilici S; Chancellor J; Löthgren M; Simon D; Said G; Le TK; Garcia-Cebrian A; Monz B
BMC Neurol; 2009 Feb; 9():6. PubMed ID: 19208243
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.
Wu EQ; Birnbaum HG; Mareva MN; Le TK; Robinson RL; Rosen A; Gelwicks S
J Pain; 2006 Jun; 7(6):399-407. PubMed ID: 16750796
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
Tanenberg RJ; Irving GA; Risser RC; Ahl J; Robinson MJ; Skljarevski V; Malcolm SK
Mayo Clin Proc; 2011 Jul; 86(7):615-26. PubMed ID: 21719618
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Iyengar S; Webster AA; Hemrick-Luecke SK; Xu JY; Simmons RM
J Pharmacol Exp Ther; 2004 Nov; 311(2):576-84. PubMed ID: 15254142
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.
Raskin J; Wang F; Pritchett YL; Goldstein DJ
Pain Med; 2006; 7(5):373-85. PubMed ID: 17014595
[TBL] [Abstract][Full Text] [Related]
11. Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.
Irving G; Tanenberg RJ; Raskin J; Risser RC; Malcolm S
Int J Clin Pract; 2014 Sep; 68(9):1130-40. PubMed ID: 24837444
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine.
Scheinfeld N
Dermatol Online J; 2013 Nov; 19(11):20616. PubMed ID: 24314785
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
Raskin J; Pritchett YL; Wang F; D'Souza DN; Waninger AL; Iyengar S; Wernicke JF
Pain Med; 2005; 6(5):346-56. PubMed ID: 16266355
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis.
Rudroju N; Bansal D; Talakokkula ST; Gudala K; Hota D; Bhansali A; Ghai B
Pain Physician; 2013; 16(6):E705-14. PubMed ID: 24284851
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.
Armstrong DG; Chappell AS; Le TK; Kajdasz DK; Backonja M; D'Souza DN; Russell JM
Pain Med; 2007; 8(5):410-8. PubMed ID: 17661854
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions.
Wernicke JF; Prakash A; Kajdasz DK; Houston J
J Diabetes Complications; 2009; 23(5):349-59. PubMed ID: 18768332
[TBL] [Abstract][Full Text] [Related]
17. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Boyle J; Eriksson ME; Gribble L; Gouni R; Johnsen S; Coppini DV; Kerr D
Diabetes Care; 2012 Dec; 35(12):2451-8. PubMed ID: 22991449
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.
Pritchett YL; McCarberg BH; Watkin JG; Robinson MJ
Pain Med; 2007; 8(5):397-409. PubMed ID: 17661853
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.
Beard SM; McCrink L; Le TK; Garcia-Cebrian A; Monz B; Malik RA
Curr Med Res Opin; 2008 Feb; 24(2):385-99. PubMed ID: 18157921
[TBL] [Abstract][Full Text] [Related]
20. Does treatment with duloxetine for neuropathic pain impact glycemic control?
Hardy T; Sachson R; Shen S; Armbruster M; Boulton AJ
Diabetes Care; 2007 Jan; 30(1):21-6. PubMed ID: 17192327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
